首页> 外文期刊>Hemodialysis international >Reduction in catheter-related infections after switching from povidone-iodine to chlorhexidine for the exit-site care of tunneled central venous catheters in children on hemodialysis
【24h】

Reduction in catheter-related infections after switching from povidone-iodine to chlorhexidine for the exit-site care of tunneled central venous catheters in children on hemodialysis

机译:从聚维酮碘转换为氯己定后,可减少儿童血液透析隧道中心静脉导管的出口现场护理,从而减少导管相关感染

获取原文
获取原文并翻译 | 示例
       

摘要

Only a few studies have investigated the optimal exit site management of tunneled central venous catheters (CVCs) in pediatric patients on chronic hemodialysis (HD). The aim of this study was to assess the efficacy of chlorhexidine solutions and a 5% povidone-iodine solution on the incidence of CVC-related infections in children on HD. The incidence of exit-site infection (ESI), tunnel infection (TI), and bloodstream infection (BSI) was assessed in two groups of tunneled CVCs. The iodopovidone group consisted of 14 CVCs used between 1 January 2011 and 30 June 2012 in 10 children, whose median age at the time of CVC placement was 11.8 years (range 1.2-19.2): 5% povidone-iodine was used for CVC exit-site care. From 1 August 2012 to 31 January 2014, 0.5% chlorhexidine gluconate/70% isopropyl alcohol was used for the exit site, and 2% chlorhexidine gluconate/70% isopropyl alcohol spray for the hub in 13 CVCs was used in 10 patients (chlorhexidine group), whose median age at the time of CVC placement was 10 years (range 1.2-19.2). Ten episodes of ESI were diagnosed in the iodopovidone group (incidence 3.4/1000 CVC days), and only one in the chlorhexidine group (incidence 0.36/1000 CVC days, P=0.008). One TI was observed in the iodopovidone group (0.34/1000 CVC days), and none in the chlorhexidine group. The incidence of BSIs decreased from 1.7/1000 CVC days (5 cases) to 0.36/1000 CVC days (1 case, P=0.06) after switching to chlorhexidine. Two CVCs were lost due to CVC-related infections in the iodopovidone group, whereas no CVC was lost due to infections in the chlorhexidine group. In comparison with 5% povidone-iodine, the use of chlorhexidine gluconate was associated with a reduction in the incidence of ESI, TI, and BSI in children on HD.
机译:仅有少数研究调查了小儿慢性血液透析(HD)患者中隧道中央静脉导管(CVC)的最佳出口部位管理。这项研究的目的是评估洗必泰溶液和5%聚维酮碘溶液对HD患儿CVC相关感染发生率的疗效。在两组隧道CVC中评估了出口部位感染(ESI),隧道感染(TI)和血流感染(BSI)的发生率。碘伏维酮组由2011年1月1日至2012年6月30日之间使用的14个CVC组成,其中10个孩子的CVC植入时的中位年龄为11.8岁(范围1.2-19.2):5%的聚维酮碘用于CVC出口,现场护理。从2012年8月1日至2014年1月31日,使用10%患者的出口部位使用0.5%葡萄糖酸氯己定/ 70%异丙醇和2%葡萄糖酸氯己定/ 70%异丙醇喷雾治疗13例CVC中的患者(氯己定组) ),其在CVC植入时的中位年龄为10岁(范围1.2-19.2)。碘伏维酮组诊断为ESI发作10次(发生率3.4 / 1000 CVC天),洗必泰组诊断为1次(发生率0.36 / 1000 CVC天,P = 0.008)。在碘维维酮组(0.34 / 1000 CVC天)中观察到1个TI,在洗必泰组中没有观察到。改用洗必泰后,BSI的发生率从1.7 / 1000 CVC天(5例)降至0.36 / 1000 CVC天(1例,P = 0.06)。在碘伏维酮组中,有两个CVC因与CVC相关的感染而丢失,而在洗必泰组中,没有CVC因感染而丢失。与5%聚维酮碘相比,使用洗必泰葡萄糖酸盐可降低HD儿童的ESI,TI和BSI发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号